Pancreatic Cancer

San Francisco, CA—Platinum-based therapy represents a new standard of care in patients with pancreatic cancer and germline BRCA or PALB2 mutation, based on data reported at the 2020 Gastrointestinal Cancers Symposium.
Pancreatic cancer is a difficult to treat malignancy with a high mortality rate. Patients are usually diagnosed with advanced disease, and many are not eligible for surgery. Although systemic therapy is a mainstay of treatment, there are limited options for patients with metastatic disease. We invite you to read more about some of the recent observational data on metastatic pancreatic cancer treatment patterns, patient outcomes, and costs in an effort to shed insights into real-world clinical decisions and the economic factors that influence them.
Maintenance therapy with the targeted drug olaparib (Lynparza) after first-line platinum-based chemotherapy prolonged progression-­free survival (PFS) in patients with metastatic pancreatic cancer and a germ­line BRCA mutation, according to results of the phase 3 POLO clinical trial presented at the plenary session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
A novel tumor metabolism-altering oral regimen that combines a tyrosine derivative (D,L-­alpha-metyrosine) with 3 repurposed agents (sirolimus, phenytoin, and methoxsalen) has demonstrated promising activity in patients with previously treated metastatic pancreatic cancer.
By improving chemotherapy-induced peripheral neuropathy (CIPN), administration of duloxetine may enable patients with advanced pancreatic cancer to continue their treatment regimen of gemcitabine plus nab-paclitaxel.

Results 1 - 5 of 5